Image-Guided Surgery (IGS) and Personalised Postoperative Immunotherapy To Improving Cancer Outcome

From 2016-01-01 to 2019-12-31, ongoing project | ISPIC Website

Project details

<table>
<thead>
<tr>
<th>Total cost:</th>
<th>Topic(s):</th>
</tr>
</thead>
<tbody>
<tr>
<td>EUR 3 922 309,44</td>
<td>MSCA-ITN-2015-ETN - Marie Skłodowska-Curie Innovative Training Networks (ITN-ETN)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EU contribution:</th>
<th>Funding scheme:</th>
</tr>
</thead>
<tbody>
<tr>
<td>EUR 3 922 309,44</td>
<td>MSCA-ITN-ETN - European Training Networks</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Coordinated in:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Netherlands</td>
</tr>
</tbody>
</table>

Objective

The basic concept of our proposal is to develop nanoparticle-based encapsulated libraries of different immunotherapeutic biomolecules for treatment after surgery as part of a novel cancer management strategy. The current state-of-art for the management of cancer starts with surgery, after identification of an accessible tumour mass. Surgery remains an effective treatment option for many types of cancer today and it is considered curative treatment for most solid tumours. It forms part of a multidisciplinary approach used in conjunction with radiotherapy or chemotherapy. These approaches, however, have several limitations, including inability of surgical resection to affect distal metastatic disease, toxicity to healthy tissues with chemotherapy and lack of effectiveness of radiation therapy in more aggressive tumours. The observation that cancer can relapse months or years after initial surgery implies that micrometastases still resides within the body in a latent state. Our proposal is to take cancer therapy to beyond state-of-art by implementing techniques which will take us into new directions.

This includes a) new methods to identify immune gene profiles and biomarkers b) transgenic mouse models where the complex interactions that underlie immune function can be visualised as multiplexed events in real time and c) the use of nanoparticle-based libraries of immune modulating reagent combinations. There are three key objectives within this project: i) to use immune gene signatures to monitor disease progression and therapeutic efficacy of immunotherapy combinations on nanoparticle-based platforms, ii) to optimise the platform to encapsulate libraries of immune components for more personalised, accurate and timely delivery of the payload to its intended target and iii) to optimise the overall cancer management process of image-guided surgery followed by postoperative immunotherapy so that we can ultimately provide a lifetime of protection against cancer.

Related information

Report Summaries

Periodic Reporting for period 1 - ISPIC (Image-Guided Surgery (IGS) and Personalised Postoperative Immunotherapy To Improving Cancer Outcome)
Coordinator

PERCUROS BV
PLESMANLAAN 1
2333 BZ LEIDEN
Netherlands

EU contribution: EUR 255,374,28

Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)

Contact the organisation

Participants

ACADEMISCH ZIEKENHUIS LEIDEN
ALBINUSDREEF 2
2333 ZA LEIDEN
Netherlands

EU contribution: EUR 680,998,08

Activity type: Higher or Secondary Education Establishments

Contact the organisation

TECHNISCHE UNIVERSITEIT DELFT
STEWINWEG 1
2628 CN DELFT
Netherlands

EU contribution: EUR 212,811,90

Activity type: Higher or Secondary Education Establishments

Contact the organisation

UNIVERSITA DEGLI STUDI DI CAMERINO
PIAZZA CAVOUP 19F
62032 CAMERINO
Italy

EU contribution: EUR 258,061,32

Activity type: Higher or Secondary Education Establishments

Contact the organisation

TECOBIOSCIENCES GMBH
HABICHTSTRASSE 21
84036 LANDSHUT
Germany

EU contribution: EUR 249,216,48

Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)

Contact the organisation
UNIVERSITEIT VAN AMSTERDAM
SPUI 21
1012WX AMSTERDAM
Netherlands
See on map

**Activity type:** Higher or Secondary Education Establishments

Contact the organisation

**EU contribution:** EUR 127,687,14

UNIVERSITETET I BERGEN
MUSEPLASSEN 1
5020 BERGEN
Norway
See on map

**Activity type:** Higher or Secondary Education Establishments

Contact the organisation

**EU contribution:** EUR 286,275,24

HELSE BERGEN HF*HAUKELAND UNIVERSITY HOSPITAL
JONAS LIES VEI 65
5021 BERGEN
Norway
See on map

**Activity type:** Higher or Secondary Education Establishments

Contact the organisation

**EU contribution:** EUR 286,275,24

ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE
BATIMENT CE 3316 STATION 1
1015 LAUSANNE
Switzerland
See on map

**Activity type:** Higher or Secondary Education Establishments

Contact the organisation

**EU contribution:** EUR 265,226,76

THE UNIVERSITY OF SHEFFIELD
FIRTH COURT WESTERN BANK
S10 2TN SHEFFIELD
United Kingdom
See on map

**Activity type:** Higher or Secondary Education Establishments

Contact the organisation

**EU contribution:** EUR 546,575,76
UNIVERSITEIT MAASTRICHT  
Minderbroedersberg 4-6  
6200 MD MAASTRICHT  
Netherlands  
See on map  

**Activity type:** Higher or Secondary Education Establishments  
Contact the organisation

JENACELL GMBH  
WINZERLAER STR 2  
07745 JENA  
Germany  
See on map  

**Activity type:** Private for-profit entities (excluding Higher or Secondary Education Establishments)  
Contact the organisation

MEDRES-MEDICAL RESEARCH GMBH  
GLEUELER STRASSE 50  
50931 KOLN  
Germany  
See on map  

**Activity type:** Private for-profit entities (excluding Higher or Secondary Education Establishments)  
Contact the organisation

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM  
DR MOLEWATERPLEIN 40  
3015 GD ROTTERDAM  
Netherlands  
See on map  

**Activity type:** Higher or Secondary Education Establishments  
Contact the organisation

---

**Last updated on** 2019-07-15  
**Retrieved on** 2019-11-26  

**Permalink:** [https://cordis.europa.eu/project/rcn/198305_en.html](https://cordis.europa.eu/project/rcn/198305_en.html)  
© European Union, 2019